GlassScriptPhysician profile
Thomas J Nowotny
NPI 1134284904
$15,629.19
in general payments reported to CMS, 2019-2025
36 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,667 · 2020: $1,802 · 2021: $2,088 · 2022: $1,647 · 2023: $1,890 · 2024: $2,802 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,724 · Debt Forgiveness: $669 · Education: $31.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,724.15 |
| Debt Forgiveness | $668.80 |
| Education | $31.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,690.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,489.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,351.97 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,332.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,101.40 | 2019-2025 | Trintellix |
| Neuronetics, INC. | $1,080.58 | 2019-2024 | Neurostar Tms Therapy System |
| Alkermes, INC. | $1,045.16 | 2019-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $924.32 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $797.08 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $724.07 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $651.73 | 2019-2025 | Rexulti |
| Allergan, INC. | $580.90 | 2019-2020 | |
| Bausch Health US, LLC | $400.03 | 2019-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $336.74 | 2019-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $306.70 | 2020-2025 | Fanapt |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $269.99 | 2019-2025 | Uzedy, Austedo |
| Corium, LLC | $237.00 | 2021-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $188.95 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $168.81 | 2020-2025 | Ingrezza |
| Noven Therapeutics, LLC | $151.92 | 2023-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $134.28 | 2022-2025 | Dyanavel Xr |
| Eisai INC. | $113.53 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $72.79 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $69.19 | 2019-2021 | |
| Neos Therapeutics, LP | $67.28 | 2019 | |
| Ironshore Pharmaceuticals INC. | $65.02 | 2019-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $52.83 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $45.55 | 2019 | |
| Luye Pharma (USA) LTD. | $40.75 | 2025 | Erzofri Extended-Release |
| Owp Pharmaceuticals, INC. | $39.83 | 2021-2024 | Subvenite |
| Shire North American Group INC | $26.33 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.03 | 2019 | |
| Tms Neurohealth Centers INC. | $15.89 | 2025 | Tms Neurohealth Centers INC. |
| Almatica Pharma LLC | $14.24 | 2023 | Gralise |
| Validus Pharmaceuticals LLC | $13.98 | 2025 | Raldesy |
| Indivior INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Nowotny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.